Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment

No abstract is available for this paper.

• Publication year

  2013

• Venue

  American journal of hematology/oncology

• Publication date

  2013-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ajh.23491PMID 23720127
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in

  2013cited by this paper
• An evidence-based review of obatoclax mesylate in the treatment of hematological malignancies

  2013cited by this paper
• ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

  2013cited by this paper
• ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia.

  2013cited by this paper
• Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factor.

  2013cited by this paper
• Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia.

  2013cited by this paper
• Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  2013cited by this paper
• Souers AJ, Leverson JD, Boghaert ER et al.ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202-208

  2013cited by this paper
• ABT-199: taking dead aim at BCL-2.

  2013cited by this paper
• Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

  2013cited by this paper
• The role of minimal residual disease measurements in the therapy for CLL: is it ready for prime time?

  2013cited by this paper
• Comparison of the Effects of Two Kinase Inhibitors, Sorafenib and Dasatinib, on Chronic Lymphocytic Leukemia Cells

  2012cited by this paper
• Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia.

  2012cited by this paper
• Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule.

  2012cited by this paper
• Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.

  2012cited by this paper
• Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.

  2012cited by this paper
• Anti-CD20 antibody therapy for B-cell lymphomas.

  2012cited by this paper
• Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia

  2012cited by this paper
• Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.

  2012cited by this paper
• CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies

  2012cited by this paper
• Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia

  2012cited by this paper
• Novel and emerging drugs for chronic lymphocytic leukemia.

  2012cited by this paper
• Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.

  2012cited by this paper
• A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia

  2012cited by this paper
• The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells

  2012cited by this paper
• Action of novel CD37 antibodies on chronic lymphocytic leukemia cells

  2012cited by this paper
• Novel CD20 monoclonal antibodies for lymphoma therapy

  2012cited by this paper
• Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients.

  2012cited by this paper
• Phase II trial of the combination of ofatumumab and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL).

  2012cited by this paper
• Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial.

  2012cited by this paper
• A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies.

  2011cited by this paper
• Tipping the Noxa/Mcl-1 Balance Overcomes ABT-737 Resistance in Chronic Lymphocytic Leukemia

  2011cited by this paper
• Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.

  2011cited by this paper
• Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro‐survival microenvironmental signals

  2011cited by this paper
• Comparison of the in vitro effects of the anti‐CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells

  2011cited by this paper
• Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia

  2011cited by this paper
• Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

  2011cited by this paper
• Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

  2011cited by this paper
• Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial.

  2011cited by this paper
• Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia.

  2011cited by this paper
• The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.

  2011cited by this paper
• Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia

  2011cited by this paper
• Prognostic factors in chronic lymphocytic leukemia—what do we need to know?

  2011cited by this paper
• Activity of Combined Flavopiridol and Lenalidomide in Patients with Cytogenetically High Risk Chronic Lymphocytic Leukemia (CLL): Updated Results of a Phase I Trial,

  2011cited by this paper
• B-cell receptor signaling in chronic lymphocytic leukemia.

  2011cited by this paper
• VSV oncolysis in combination with the BCL-2 inhibitor obatoclax overcomes apoptosis resistance in chronic lymphocytic leukemia.

  2010cited by this paper
• Phase 1 Trial of Flavopiridol and Lenalidomide In Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL)

  2010cited by this paper
• Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia

  2010cited by this paper
• From pathogenesis to treatment of chronic lymphocytic leukaemia

  2010cited by this paper
• Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma.

  2010cited by this paper
• Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101.

  2010cited by this paper
• Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.

  2010cited by this paper
• Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.

  2010cited by this paper
• A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma

  2010cited by this paper
• Preliminary Results From a Phase I/II Study of Fludarabine, Rituximab, and Lenalidomide In Untreated Patients with Chronic Lymphocytic Leukemia (CLL)

  2010cited by this paper
• A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia

  2010cited by this paper
• A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154

  2010cited by this paper
• Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.

  2010cited by this paper
• Rituximab for the Treatment of Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukaemia

  2010cited by this paper
• CNS Disease In Younger Patients (

  2010cited by this paper
• A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL

  2010cited by this paper
• Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics

  2010cited by this paper
• Combination of Ofatumumab and Lenalidomide In Patients with Relapsed Chronic Lymphocytic Leukemia: Initial Results of a Phase II Trial

  2010cited by this paper
• TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations

  2010cited by this paper
• Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.

  2010cited by this paper
• The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation

  2010cited by this paper
• The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia.

  2010cited by this paper
• Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

  2010cited by this paper
• The REVLIRIT CLL5 AGMT Study - a Phase I/II Trial Combining Fludarabine/Rituximab with Escalating Doses of Lenalidomide Followed by Rituximab/Lenalidomide in Untreated Chronic Lymphocytic Leukemia (CLL): Results of a Planned Interim Analysis.

  2009cited by this paper
• The humanized CD40 antibody SGN‐40 demonstrates pre‐clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia

  2009cited by this paper
• Phase I Study of RO5072759 (GA101) in Relapsed/Refractory Chronic Lymphocytic Leukemia.

  2009cited by this paper
• Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.

  2009cited by this paper
• Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab

  2009cited by this paper
• TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies.

  2009cited by this paper
• Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia.

  2009cited by this paper
• Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia.

  2009cited by this paper
• The microenvironment in mature B-cell malignancies: a target for new treatment strategies.

  2009cited by this paper
• Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma.

  2009cited by this paper
• Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.

  2009cited by this paper
• Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.

  2009cited by this paper
• AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance.

  2009cited by this paper
• State-of-the-art treatment of chronic lymphocytic leukemia.

  2009cited by this paper
• Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells

  2009cited by this paper
• The DNA-damage response in human biology and disease

  2009cited by this paper
• Consolidation with alemtuzumab improves progression‐free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission – long‐term follow‐up of a randomized phase III trial of the German CLL Study Group (GCLLSG)

  2009cited by this paper
• Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia.

  2009cited by this paper
• A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL

  2009cited by this paper
• Disease burden of chronic lymphocytic leukaemia within the European Union

  2008cited by this paper
• Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

  2008cited by this paper
• Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody

  2008cited by this paper
• Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro

  2008cited by this paper
• ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.

  2008cited by this paper
• Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.

  2008cited by this paper
• The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes.

  2008cited by this paper
• Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro.

  2008cited by this paper
• Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.

  2008cited by this paper
• Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.

  2007cited by this paper
• Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.

  2007cited by this paper
• Clinical Efficacy of Lenalidomide in Fludarabine-Refractory Chronic Lymphocytic Leukemia Patients.

  2007cited by this paper
• Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia.

  2007cited by this paper

• Gender Disparities in Health‐Related Quality of Life in Patients With Chronic Lymphocytic Leukemia: Impact of Treatment Modality

  2025cites this paper
• Cyclin-dependent Kinase 5 and Neurodegenerative Diseases

  2024cites this paper
• Maintenance therapy for chronic lymphocytic leukaemia.

  2024cites this paper
• Biomarkers for predicting response to corticosteroid therapy for immune thrombocytopenic purpura

  2023cites this paper
• A Peculiar CLL Case with Complex Chromosome 6 Rearrangements and Refinement of All Breakpoints at the Gene Level by Genomic Array: A Case Report

  2023cites this paper
• Role of the Dietary Phytochemical Curcumin in Targeting Cancer Cell Signalling Pathways

  2023cites this paper
• Autoimmune cytopenias in chronic lymphocytic leukemia: a growing challenge in targeted therapies?

  2022cites this paper
• Expression of CTLA-4 and CD86 Antigens and Epstein-Barr Virus Reactivation in Chronic Lymphocytic Leukemia—Any Link with Known Prognostic Factors?

  2022cites this paper
• Trends in Disease Burden of Chronic Lymphocytic Leukemia at the Global, Regional, and National Levels From 1990 to 2019, and Projections Until 2030: A Population-Based Epidemiologic Study

  2022cites this paper
• TGF-β/SMAD Pathway Is Modulated by miR-26b-5p: Another Piece in the Puzzle of Chronic Lymphocytic Leukemia Progression

  2022cites this paper
• Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges

  2021cites this paper
• Prognostic significance of ATM mutations in chronic lymphocytic leukemia: A meta-analysis.

  2021cites this paper
• Pharmacological relevance of CDK inhibitors in Alzheimer's disease.

  2021cites this paper
• Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia: A Comprehensive Review

  2021cites this paper
• The Role of Curcumin in Cancer Treatment

  2021cites this paper
• The Determinants of B Cell Receptor Signaling as Prototype Molecular Biomarkers of Leukemia

  2021cites this paper
• Potential Role of Curcumin and Its Nanoformulations to Treat Various Types of Cancers

  2021cites this paper
• Expression of Surface-associated 82 kDa proMMP-9 in Lymphatic Leukemia Blast Cells Differentially Correlates With Prognosis

  2021cites this paper
• Mathematical and Systems Medicine Approaches to Resistance Evolution and Prevention in Cancer

  2021cites this paper
• Bone Marrow Lymphoid Niche Adaptation to Mature B Cell Neoplasms

  2021cites this paper
• The Anti-Leukemic Activity of Natural Compounds

  2021cites this paper
• Leukemia: Trends in treatment and how close we have achieved eradication

  2021cites this paper
• Additional B-cell malignancies in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL)

  2020cites this paper
• Autoimmune Complications in Chronic Lymphocytic Leukemia in the Era of Targeted Drugs

  2020cites this paper
• Coexistence Simultanée D’une Leucémie Lymphoïde Chronique Et D’une Leucémie Myéloïde Chronique : Une Première Observation Au Togo

  2020cites this paper
• Detection of somatic TP53 mutations and 17p deletions in patients with chronic lymphocytic leukemia: a review of the current methods

  2020cites this paper
• Inactivated STAT5 pathway underlies a novel inhibitory role of EBF1 in chronic lymphocytic leukemia.

  2020cites this paper
• Telomere Length and Hematological Disorders: A Review

  2020cites this paper
• Autoimmune haemolytic anaemia and a marked rise in the lymphocyte count associated with COVID‐19 in a patient with treatment‐naïve chronic lymphocytic leukaemia: a case report

  2020cites this paper
• Programmed cell death 1 expression and Epstein-Barr virus infection in chronic lymphocytic leukaemia: a prospective cohort study

  2019cites this paper
• Curcumin as a therapeutic agent in leukemia

  2019cites this paper
• Maintenance therapy for chronic lymphocytic leukaemia

  2019cites this paper
• Massive lymphadenopathy and hypereosinophilia in cd5-negative small lymphocytic lymphoma

  2019cites this paper
• Expression Profiles of miR-93 and miR-330 in Iranian Patients with Chronic Lymphocytic Leukemia

  2019cites this paper
• The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia

  2019cites this paper
• Bacterial Colonization in Patients with Chronic Lymphocytic Leukemia and Factors Associated with Infections and Colonization

  2019cites this paper
• LMW-PTP targeting potentiates the effects of drugs used in chronic lymphocytic leukemia therapy

  2019cites this paper
• MiR-486-5p inhibits the proliferation of leukemia cells and induces apoptosis through targeting FOXO1.

  2019cites this paper
• Dose and drug changes in chronic lymphocytic leukemia cell response in vitro: A comparison of standard therapy regimens with two novel cyclin-dependent kinase inhibitors

  2019cites this paper
• Assessment of microRNA expression in leukemic cells as predictors of sensitivity to purine nucleoside analogs, fludarabine and cladribine, in chronic lymphocytic leukemia patients

  2019cites this paper
• Caractéristiques de la leucémie lymphoïde chronique au Togo

  2019influential citation
• Assays on DNA Damage and Repair in CLL.

  2018cites this paper
• Identification of prognostic parameters in CLL with no abnormalities detected by chromosome banding and FISH analyses

  2018cites this paper
• Population Dynamics and Evolution of Cancer Cells

  2018cites this paper
• Advances in chronic lymphocytic leukemia pharmacotherapy.

  2018cites this paper
• Characterizing patients with multiple chromosomal aberrations detected by FISH in chronic lymphocytic leukemia

  2018cites this paper
• The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL.

  2018cites this paper
• Clinicohematological parameters and outcomes in a cohort of chronic lymphocytic leukemia patients with Deletion 17p from Pakistan

  2018cites this paper
• Disseminated histoplasmosis as a first clinical manifestation in a patient with small lymphocytic lymphoma: A case report

  2018cites this paper
• CD49d shows superior performance characteristics for flow cytometric prognostic testing in chronic lymphocytic leukemia/small lymphocytic lymphoma

  2018cites this paper
• p53: TUMOUR PROGRESSION AND THERAPY MARKER

  2018cites this paper
• The NOTCH Pathway and Its Mutations in Mature B Cell Malignancies

  2018cites this paper
• Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies

  2018cites this paper
• Canadian evidence-based guideline for the first-line treatment of chronic lymphocytic leukemia.

  2018cites this paper
• Pathologies de la muqueuse buccale chez la personne âgée : études de cas cliniques

  2018cites this paper
• Primer on Chronic Lymphocytic Leukemia: Part I

  2018cites this paper
• Management of melanoma in patients with chronic lymphocytic leukemia.

  2018cites this paper
• Lymphomatoid papulosis associated with chronic lymphocytic leukaemia/small lymphocytic lymphoma: three cases

  2018cites this paper
• The Frequency and Prognostic Value of Neutrophilia in Chronic Lymphocytic Leukemia

  2018cites this paper
• Autoimmune cytopenias in chronic lymphocytic leukemia: a concise review and treatment recommendations

  2018cites this paper
• Host virus and pneumococcus-specific immune responses in high-count monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia: implications for disease progression

  2017cites this paper
• Targeted activation of the SHP-1/PP2A signaling axis elicits apoptosis of chronic lymphocytic leukemia cells

  2017cites this paper
• No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy

  2017cites this paper
• Leukemieën en myelodysplasie

  2017cites this paper
• Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment

  2017cites this paper
• Immunophenotypic Characterization of Patients with Chronic Lymphocytic Leukemia by Flow Cytometry; Association with Disease Prognosis

  2017cites this paper
• Significance of Frequencies, Compositions, and/or Antileukemic Activity of (DC-stimulated) Invariant NKT, NK and CIK Cells on the Outcome of Patients With AML, ALL and CLL

  2017cites this paper
• Cytogenetic and molecular cytogenetic investigations in relapse of B-cell chronic lymphocytic leukemia

  2017cites this paper
• Idelalisib or Placebo in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL - Interim Results of a Phase 3 Randomized, Double-blind Placebo-Controlled Trial

  2017cites this paper
• Idelalisib or Placebo in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL - Interim Results of a Phase 3 Randomized, Double-blind Placebo-Controlled Trial

  2017cites this paper
• Phytochemicals as an adjuvant in leukemia therapy

  2017cites this paper
• Nutraceuticals in leukemia

  2017cites this paper
• Caractérisation fonctionnelle du récepteur de type 2 de la neurotensine dans la résistance à la mort cellulaire des lymphocytes B au cours de la Leucémie Lymphoïde Chronique

  2017cites this paper
• Nuevas aportaciones de la hibridación in situ fluorescente y el estado mutacional del gen de las cadenas pesadas de inmunoglobulinas para predecir el curso clínico de los pacientes con leucemia linfocítica crónica

  2017cites this paper
• Diferenciación plasmocelular en linfomas no-Hodgkin de células B: implicaciones clínicas y terapéuticas

  2017cites this paper
• Cholesterol Levels in Patients with Chronic Lymphocytic Leukemia.

  2017cites this paper
• The prohibitin-binding compound fluorizoline induces apoptosis in chronic lymphocytic leukemia cells through the upregulation of NOXA and synergizes with ibrutinib , AICAR or venetoclax

  2017cites this paper
• Composite Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Cell Lymphoma with 17p Deletion: A Case Study

  2017cites this paper
• Examining the medical resource utilization and costs of relapsed and refractory chronic lymphocytic leukemia in Ontario.

  2017cites this paper
• The prohibitin-binding compound fluorizoline induces apoptosis in chronic lymphocytic leukemia cells through the upregulation of NOXA and synergizes with ibrutinib, 5-aminoimidazole-4-carboxamide riboside or venetoclax

  2017cites this paper
• Features based on the percolation theory for quantification of non-Hodgkin lymphomas

  2017cites this paper
• Prognostički značaj fluorescencijske in situ hibridizacije (FISH) u bolesnika s kroničnom limfocitnom leukemijom

  2017cites this paper
• Chromosomal abnormalities in bone marrow cells in relapse of chronic lymphocytic leukemia

  2017cites this paper
• NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components

  2017cites this paper
• Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

  2017cites this paper
• A rare case of atypical chronic lymphocytic leukaemia presenting as nephrotic syndrome

  2017cites this paper
• Telomere shortening, TP53 mutations and deletions in chronic lymphocytic leukemia result in increased chromosomal instability and breakpoint clustering in heterochromatic regions

  2017cites this paper
• Chapter 8 New Insights in Prognosis and Therapy of Chronic Lymphocytic Leukaemia

  2017cites this paper
• Two distinct molecular subtypes of chronic lymphocytic leukemia give new insights on the pathogenesis of the disease and identify novel therapeutic targets

  2016cites this paper
• Green tea polyphenol "epigallocatechin-3-gallate", differentially induces apoptosis in CLL B-and T-Cells but not in healthy B-and T-Cells in a dose dependant manner.

  2016cites this paper
• Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.

  2016cites this paper
• Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors.

  2016cites this paper
• Assessment of red blood cell distribution width as a prognostic marker in chronic lymphocytic leukemia

  2016cites this paper
• Angiopoietins Modulate Survival, Migration, and the Components of the Ang-Tie2 Pathway of Chronic Lymphocytic Leukaemia (CLL) Cells In Vitro

  2016cites this paper
• NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation

  2016cites this paper
• Standards for specialist laboratory integration and Dataset for the histopathological reporting of lymphomas October 2015

  2016cites this paper
• Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin’s Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis

  2016cites this paper
• Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations

  2016cites this paper
• Secondary immunodeficiency in lymphoproliferative malignancies

  2016cites this paper
• t(14;18)(q32;q21) in chronic lymphocytic leukemia patients: Report of two cases and a literature review

  2016influential citation